Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
United Therapeutic (UTHR)
United Therapeutic (UTHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,176,106
  • Shares Outstanding, K 46,847
  • Annual Sales, $ 1,936 M
  • Annual Income, $ 727,300 K
  • 60-Month Beta 0.60
  • Price/Sales 5.16
  • Price/Cash Flow 12.28
  • Price/Book 1.92
Trade UTHR with:

Options Overview Details

View History
  • Implied Volatility 25.89% ( -1.38%)
  • Historical Volatility 23.91%
  • IV Percentile 1%
  • IV Rank 10.18%
  • IV High 45.88% on 10/13/22
  • IV Low 23.62% on 05/19/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 26
  • Volume Avg (30-Day) 156
  • Put/Call OI Ratio 1.47
  • Today's Open Interest 3,360
  • Open Int (30-Day) 4,278

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate 4.45
  • Number of Estimates 8
  • High Estimate 4.98
  • Low Estimate 4.17
  • Prior Year 2.41
  • Growth Rate Est. (year over year) +84.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
204.44 +6.25%
on 05/30/23
224.04 -3.04%
on 05/03/23
-11.57 (-5.06%)
since 05/02/23
3-Month
204.44 +6.25%
on 05/30/23
249.21 -12.84%
on 03/03/23
-27.54 (-11.25%)
since 03/02/23
52-Week
201.65 +7.72%
on 09/22/22
283.09 -23.27%
on 12/09/22
-11.01 (-4.82%)
since 06/02/22

Most Recent Stories

More News
4 Best Biotech Stocks According to POWR Ratings

Rapid advancements and soaring demand make the biotech sector well-positioned to witness significant growth in the foreseeable future. Given this backdrop, quality biotech stocks Amgen Inc. (AMGN), Regeneron...

AMGN : 218.07 (+1.77%)
REGN : 739.95 (+1.20%)
UTHR : 217.22 (+1.75%)
VNDA : 6.06 (+2.71%)
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

DNLI : 31.52 (+1.94%)
RARE : 50.85 (+2.50%)
SRPT : 125.16 (+0.71%)
PFE : 38.36 (+0.89%)
EXEL : 19.19 (-1.03%)
MRNA : 130.51 (+1.55%)
UTHR : 217.22 (+1.75%)
BIIB : 300.20 (-0.73%)
SNY : 51.01 (+1.09%)
LLY : 442.33 (+1.34%)
Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q1 Earnings

The headline numbers for United Therapeutics (UTHR) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street...

UTHR : 217.22 (+1.75%)
United Therapeutics (UTHR) Q1 Earnings Beat Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 11.72% and 1.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

UTHR : 217.22 (+1.75%)
ONCT : 0.3060 (+2.55%)
United Therapeutics: Q1 Earnings Snapshot

United Therapeutics: Q1 Earnings Snapshot

UTHR : 217.22 (+1.75%)
United Therapeutics Corporation Reports First Quarter 2023 Financial Results

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2023. Total revenues in the first quarter of 2023 grew...

UTHR : 217.22 (+1.75%)
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More

Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.

UTHR : 217.22 (+1.75%)
PCRX : 39.09 (+2.76%)
AMRN : 1.2800 (+5.79%)
CORT : 23.26 (+1.26%)
IONS : 41.75 (-2.77%)
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Relay Therapeutics, Inc. (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RLAY : 11.47 (+3.71%)
UTHR : 217.22 (+1.75%)
Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UTHR : 217.22 (+1.75%)
SAGE : 49.82 (+0.52%)
United Therapeutics Corporation to Report First Quarter 2023 Financial Results Before the Market Opens on Wednesday, May 3, 2023

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will report its first quarter 2023 financial results before the market opens on Wednesday, May 3, 2023.

UTHR : 217.22 (+1.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by...

See More

Key Turning Points

3rd Resistance Point 223.63
2nd Resistance Point 220.65
1st Resistance Point 218.94
Last Price 217.22
1st Support Level 214.25
2nd Support Level 211.27
3rd Support Level 209.56

See More

52-Week High 283.09
Fibonacci 61.8% 251.98
Fibonacci 50% 242.37
Fibonacci 38.2% 232.76
Last Price 217.22
52-Week Low 201.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar